{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:33:11Z","timestamp":1763105591664,"version":"3.37.3"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,4,29]],"date-time":"2018-04-29T00:00:00Z","timestamp":1524960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is strong evidence that alopecia areata is of immunological background; Interleukin\u201017 (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017) is a Th17 pro\u2010inflammatory cytokine that has been allied to the pathogenesis of different autoimmune and inflammatory diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to measure serum <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A in patients with alopecia areata, and to study associations between <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A levels and disease severity before and after Narrowband\u2010Ultraviolet B (<jats:styled-content style=\"fixed-case\">NB<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">UVB<\/jats:styled-content>), patient gender and age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty patients with <jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content> of the scalp were treated with (<jats:styled-content style=\"fixed-case\">NB<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">UVB<\/jats:styled-content>), and 15 healthy subjects' age and sex matched were enrolled as controls. Patients were assessed clinically by <jats:styled-content style=\"fixed-case\">SALT<\/jats:styled-content> score. Assay of serum levels of <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A by <jats:styled-content style=\"fixed-case\">ELISA<\/jats:styled-content> was done in patients and controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean level of <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A was (15.63 \u00c2 \u00b1 10.89 Pg\/mL) in <jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content> patient group, and (16.50 \u00c2 \u00b1 5.02 Pg\/mL) in control group. No statistically significant correlation was detected between <jats:styled-content style=\"fixed-case\">SALT<\/jats:styled-content> score and <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A level before (<jats:styled-content style=\"fixed-case\">NB<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">UVB<\/jats:styled-content>) treatment while a significant negative correlation between <jats:styled-content style=\"fixed-case\">SALT<\/jats:styled-content> score and <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A level was observed after treatment (<jats:italic>r<\/jats:italic> = \u2212.448, <jats:italic>P<\/jats:italic> = .047). Mean <jats:styled-content style=\"fixed-case\">SALT<\/jats:styled-content> score for patients was (14.03 \u00c2 \u00b1 13.48), and correlated positively with age (<jats:italic>r<\/jats:italic> = .446, <jats:italic>P<\/jats:italic> = .049).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although (<jats:styled-content style=\"fixed-case\">NB<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">UVB<\/jats:styled-content>) is an immune\u2010modulatory type of treatment for alopecia areata of mild efficacy especially if it's used alone, it has shown significant decrease in serum <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A level among patients, and correlation to disease severity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.12664","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T07:11:06Z","timestamp":1525072266000},"page":"533-537","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Correlation between serum <scp>IL<\/scp>\u201017A level and <scp>SALT<\/scp> score in patients with alopecia areata before and after <scp>NB<\/scp>\u2010<scp>UVB<\/scp> therapy"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-6516","authenticated-orcid":false,"given":"Hanan","family":"Morsy","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Andrology Faculty of Medicine Assiut University Assiut Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reham","family":"Maher","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Andrology Faculty of Medicine Assiut University Assiut Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Negm","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology Faculty of Medicine Assiut University Assiut Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,4,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03523.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.07.001"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242613"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.7.916"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2800"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12808"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12994"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12396"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1617-z"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14048456"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.09.032"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2011.00612.x"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjocd.12664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.12664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:30:44Z","timestamp":1695490244000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.12664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,29]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/jocd.12664"],"URL":"https:\/\/doi.org\/10.1111\/jocd.12664","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"type":"print","value":"1473-2130"},{"type":"electronic","value":"1473-2165"}],"subject":[],"published":{"date-parts":[[2018,4,29]]},"assertion":[{"value":"2018-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}